A Phase 2 Double-blind, Placebo-Controlled, Dose-Ranging Clinical Trial to Evaluate the Efficacy and Safety of PRAX-114 in Adjunctive and Monotherapy Treatment of Participants With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
Latest Information Update: 22 Aug 2022
At a glance
- Drugs PRAX-114 (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Acronyms Acapella
- Sponsors Praxis Precision Medicines
Most Recent Events
- 18 Aug 2022 Status changed from active, no longer recruiting to completed.
- 20 Jul 2022 Planned End Date changed from 1 Jun 2022 to 1 Jul 2022.
- 20 Jul 2022 Planned primary completion date changed from 1 Jun 2022 to 1 Jul 2022.